

G6PC expression in murine glycogen storage disease type Ia. *Mol Genet Metab.* 2013;110(3):275–80. [PMID 23856420].

*Intellectual Property:* HHS Reference No. E–552–2013/0—U.S. Provisional Patent Application No. 61/908,861 filed November 26, 2013.

*Licensing Contact:* Suryanarayana Vepa, Ph.D., J.D.; 301–435–5020; [vepas@mail.nih.gov](mailto:vepas@mail.nih.gov).

### Novel Epstein-Barr Virus Vaccines

*Description of Technology:* Epstein-Barr Virus (EBV) is the causative agent of infectious mononucleosis and is associated with certain types of cancers, such as Hodgkin's lymphoma, Burkitt's lymphoma, gastric carcinoma, and nasopharyngeal carcinoma. There are currently no vaccines against EBV on the market and there is only supportive treatment available for EBV infection.

The subject technologies are novel vaccine candidates against EBV that employ fusion proteins consisting of immunogenic portions of the EBV envelope glycoproteins (i.e. gp350, gH/gL, etc.) that are found on the surface of the virus fused with a self-assembling protein such as ferritin. The fusion proteins multimerize and the resulting nanoparticles serve as the antigens in the vaccine. In mice, these vaccine candidates were able to elicit neutralizing antibodies that were significantly higher than vaccination with only soluble forms of the EBV envelope glycoproteins lacking the self-assembly domains. In some cases, the fusion protein vaccine candidates were able to elicit neutralizing antibodies while vaccination with the corresponding soluble versions elicited primarily non-neutralizing antibodies. These neutralizing antibody titers in immunized mice were substantially higher than those seen in humans naturally infected with EBV.

*Potential Commercial Applications:* Vaccines against EBV.

*Competitive Advantages:* The subject technologies are novel vaccine candidates against EBV that were able to elicit significantly higher levels of neutralizing antibodies than vaccines based solely on soluble forms of the EBV envelope glycoproteins lacking self-assembly domains.

### Development Stage

- Early-stage
- In vitro data available
- In vivo data available (animal)

*Inventors:* Masaru Kanekiyo, Wei Bu, Jeffrey Cohen (all of NIAID).

### Intellectual Property

- HHS Reference No. E–531–2013/0–US–01—U.S. Provisional Patent Application No. 61/889,840 filed 11 Oct 2013

- HHS Reference No. E–531–2013/1–US–01—U.S. Provisional Patent Application No. 61/921,284 filed 27 Dec. 2013

*Licensing Contact:* Kevin W. Chang, Ph.D.; 301–435–5018; [changke@mail.nih.gov](mailto:changke@mail.nih.gov).

### Lentiviral Vectors To Modulate p53 Function in Human Stem Cells

*Description of Technology:* The tumor suppressor protein p53 regulates the self-renewal and pluripotency of normal and cancer stem cells, as well as the efficiency of reprogramming normal cells into induced pluripotent stem cells (iPSC). Natural human p53 isoforms delta133p53 and p53beta are the physiological inhibitor and enhancer, respectively. Researchers at the National Cancer Institute, NIH, have discovered that human embryonic stem cells (hESC) express delta133p53 protein much more abundantly than normal human fibroblasts or cancer cell lines.

Available for licensing are lentiviral vectors for constitutive over-expression of the p53 isoforms delta133p53 and p53beta, inducible over-expression of delta133p53, and inducible shRNA knock-down of delta133p53.

### Potential Commercial Applications

- Stem cell-based regenerative medicine for the treatment of age-related degenerative diseases.
- Targeting of cancer stem cells for treatment of cancer.
- Development of compounds that mimic the effects of the p53 isoforms on hESC and iPSC.
- Development of compounds that act in p53 isoform-dependent manners to regulate self-renewing vs. asymmetric cell divisions in cancer stem cells.

### Competitive Advantages

- Enhanced expression of delta133p53 for efficient hESC self-renewal and pluripotency without genome instability.
- Enhanced expression of delta133p53 for efficient reprogramming to iPSC without genome instability.
- Enhanced expression of p53beta and/or knockdown of delta133p53 for efficient induction of hESC/iPSC differentiation without unwanted cell death.

*Development Stage:* In vitro data available.

*Inventors:* Curtis C. Harris, et al. (NCI).

*Publication:* Fujita K, et al. Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. *Nat Cell Biol.* 2010 Dec;12(12):1205–12. [PMID 21057505].

*Intellectual Property:* HHS Reference No. E–137–2010/0—Research Tool. Patent protection is not being pursued for this technology.

*Related Technology:* HHS Reference No. E–239–2010/0—Retroviral and Lentiviral Vectors to Increase Efficiency of Inducible Pluripotent Stem Cell (iPSC) Production.

*Licensing Contact:* Patrick P. McCue, Ph.D.; 301–435–5560; [mccuepat@mail.nih.gov](mailto:mccuepat@mail.nih.gov).

Dated: August 6, 2014.

**Richard U. Rodriguez,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 2014–18853 Filed 8–8–14; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

### Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Advisory Committee to the Director, National Institutes of Health.

The meeting will be open to the public, the attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* Advisory Committee to the Director, National Institutes of Health.

*Date:* September 5, 2014.

*Time:* 3:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate reports from the HeLa Genome Data Access and the Stem Cell working groups.

*Place:* National Institutes of Health (Telephone Conference Call), Dial in 800–779–9282, Passcode: ACD Teleconference.

*Contact Person:* Gretchen Wood, Staff Assistant, National Institutes of Health Office of the Director, One Center Drive, Building 1, Room 126, Bethesda, MD 20892, 301–496–4272, [woodgs@od.nih.gov](mailto:woodgs@od.nih.gov).

Any member of the public interested in presenting oral comments to the committee must notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations must submit a letter of intent, a brief description of the organization represented, and a short

description of the oral presentation. Time permitting, individuals or a single representative of an organization may be allowed to present oral comments. Depending on the number of requests received, the time allotment to each presenter may be limited. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice.

The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <http://acd.od.nih.gov>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS).

Dated: August 5, 2014.

**Anna Snouffer,**

*Deputy Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2014-18846 Filed 8-8-14; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Synapses.

*Date:* August 12, 2014.

*Time:* 12:00 p.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Peter B. Guthrie, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4142, MSC 7850, Bethesda, MD 20892, (301) 435-1239, [guthriep@csr.nih.gov](mailto:guthriep@csr.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

*Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: AIDS and AIDS Related Research.

*Date:* August 15, 2014.

*Time:* 1:00 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Robert Freund, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5216, MSC 7852, Bethesda, MD 20892, 301-435-1050, [freundr@csr.nih.gov](mailto:freundr@csr.nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS).

Dated: August 1, 2014.

**Anna Snouffer,**

*Deputy Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2014-18856 Filed 8-8-14; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant

applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Small Grants to Promote Diversity.

*Date:* September 12, 2014.

*Time:* 9:00 a.m. to 1:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Elena Sanovich, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 750, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, 301-594-8886, [sanoviche@mail.nih.gov](mailto:sanoviche@mail.nih.gov).

*Name of Committee:* National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Biomarkers for Diabetes, Kidney Diseases and Urology (R01) PAR-13-228.

*Date:* September 25, 2014.

*Time:* 11:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Najma Begum, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 749, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-8894, [begumn@nidddk.nih.gov](mailto:begumn@nidddk.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: August 5, 2014.

**David Clary,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2014-18898 Filed 8-8-14; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Biomedical Imaging and Bioengineering Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and